Descrizione del progetto
Un modo intelligente per predire la progressione di malattie neurologiche
I sistemi di IA possono essere usati per sviluppare modelli in grado di predire la progressione di sclerosi multipla e sclerosi laterale amiotrofica. Pur essendo entrambe malattie neurodegenerative molto complesse, croniche e progressive, la loro evoluzione clinica, la prognosi e le terapie sono diverse. In questo contesto, il progetto BRAINTEASER, finanziato dall’UE, svilupperà un sistema di sensori indossabili per consentire previsioni nonché per far progredire processi decisionali clinici e prevenzione. Nello specifico, software e app saranno progettati per abbracciare un approccio di progettazione agile e orientato all’utente, prendendo in considerazione i bisogni tecnici, medici, psicologici e sociali del singolo utente. Uno degli obiettivi principali è assistere i medici nel suggerire interventi che possano ritardare la progressione della malattia.
Obiettivo
Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS) are chronic diseases characterized by progressive or alternate impairment of neurological functions (motor, sensory, visual, cognitive). Patients have to manage alternated periods in hospital with care at home, experiencing a constant uncertainty regarding the timing of the disease acute phases and facing a considerable psychological and economic burden that also involves their caregivers. Clinicians, on the other hand, need tools able to support them in all the phases of the patient treatment, suggest personalized therapeutic decisions, indicate urgently needed interventions.
Artificial Intelligence is the key to successfully satisfy these needs to: i) better describe disease mechanisms; ii) stratify patients according to their phenotype assessed all over the disease evolution; iii) predict disease progression in a probabilistic, time dependent fashion; iv) investigate the role of the environment; v) suggest interventions that can delay the progression of the disease.
BRAINTEASER will integrate large clinical datasets with novel personal and environmental data collected using low-cost sensors and apps. Software and mobile apps will be designed embracing an agile and user-centred design approach, accounting for the technical, medical, psychological and societal needs of the specific users.
BRAINTEASER will implement a system able to guarantee cybersecurity and data ownership to the patients; will provide quantitative evidence of benefits and effectiveness of using AI in health-care pathways implementing a proof-of-concept of its use in real clinical setting. Procedural requirements that support Software as Medical Device certification will be used involving clinicians and patients stakeholders and producing a set of recommendations for public health authorities. Results will be disseminated accordingly to an open science paradigm under the European Open Science Cloud initiative.
Campo scientifico
- natural sciencescomputer and information sciencesartificial intelligence
- natural sciencescomputer and information sciencessoftware
- medical and health scienceshealth sciencespublic health
- medical and health sciencesbasic medicineneurologymultiple sclerosis
- medical and health sciencesbasic medicineneurologyamyotrophic lateral sclerosis
Parole chiave
Programma(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SC1-DTH-2020-1
Meccanismo di finanziamento
RIA - Research and Innovation actionCoordinatore
28040 Madrid
Spagna